The study for related factors of Tolvaptan’s therapeutic effect and adverse reaction in heart failure patients based on pharmacogenomics

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900023092

Enrollment

Unknown

Registered

2019-05-10

Start date

2019-05-20

Completion date

Unknown

Last updated

2019-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

heart failure

Interventions

case series:tolvaptan

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with heart failure who are hospitalized no more than 72 hours; 2. Patients with heart failure whose LVEF is no more than 40%; 3. Patients with heart failure who have volume overload (one or more of the following symptoms:distention of jugular vein, pitting edema, pulmonary congestion).

Exclusion criteria

Exclusion criteria: 1. Patients with recent or planned vascular remodeling or device implantation; 2. Patients with ST-segment elevation myocardial infarction during hospitalization; 3. Patients with supine systolic blood pressure 3.5 mg/dL, K+ > 5.5 mEq/L,hemoglobin < 9 g/dL .

Design outcomes

Primary

Measure	Time frame
weight;blood concentration;gene detection;	—

Secondary

Measure	Time frame
24 hour urine volume;	—

Countries

China

Contacts

Public ContactAilan Chen

The First Affiliated Hospital of Guangzhou Medical University

1228327958@qq.com+86 13719198832

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026